Evidence map›Paper›PMID 38153517›Full record

ArticleBiomolecules & biomedicine2023

Cell division cycle 42 effector protein 4 inhibits prostate cancer progression by suppressing ERK signaling pathway.

Xiaowen Zhang, Tao Yu, Guojun Gao, Junbao Xu, Ruihui Lin, Zhifang Pan, Jianying Liu, Weiguo Feng

Open access · diamondAbstract read
In one paragraph

Article in Biomolecules & biomedicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Xiaowen ZhangSchool of Life Science and Technology, Weifang Medical University, Weifang, China.
Tao YuDepartment of Nuclear Medicine, The Third Affiliated Hospital of Shandong First Medical University, Jinan, China.
Guojun GaoDepartment of Urology Surgery, Affiliated Hospital of Weifang Medical University, Weifang, China.
Junbao XuCancer Center, Shandong Public Health Clinical Center, Shandong, China.
Ruihui LinSchool of Life Science and Technology, Weifang Medical University, Weifang, China.
Zhifang PanSchool of Life Science and Technology, Weifang Medical University, Weifang, China.
Jianying LiuDepartment of Nuclear Medicine, The Third Affiliated Hospital of Shandong First Medical University, Jinan, China.
Weiguo FengSchool of Life Science and Technology, Weifang Medical University, Weifang, China.
Weifang Medical University · CNShandong First Medical University · CNShanghai Public Health Clinical Center · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer (PCa) is the most common malignancy among men worldwide. The cell division cycle 42 effector protein 4 (CDC42EP4) functions downstream of CDC42, yet its role and molecular mechanisms in PCa remain unexplored. This study aimed to elucidate the role of CDC42EP4 in the progression of PCa and its underlying mechanisms. Bioinformatical analysis indicated that CDC42EP4 expression was significantly lower in PCa tissue compared to normal prostate tissue. Cellular phenotyping analysis suggested that CDC42EP4 markedly inhibited the proliferation, migration, and invasion of PCa cells. Xenograft tumor assays further demonstrated that CDC42EP4 suppressed the growth of PCa cells in vivo. Mechanistically, the study established that CDC42EP4 inhibited the ERK pathway in PCa cells. Additionally, the ERK pathway inhibitor PD0325901 was employed, revealing that PD0325901 significantly nullified the effects of CDC42EP4 on PCa cell proliferation, migration, and invasion. Collectively, our findings demonstrate that CDC42EP4 acts as a critical tumor suppressor gene, inhibiting PCa cell proliferation, migration, and invasion through the ERK pathway, thereby presenting potential targets for PCa therapy.

Indexed as

Cell MovementCell ProliferationMAP Kinase Signaling SystemProstatic NeoplasmsAnimalsCell Line, TumorDisease ProgressionGene Expression Regulation, NeoplasticHumansMaleMiceMice, NudeNeoplasm Invasiveness

Identifiers

PMID38153517
PMCPMC11293231
OpenAlexW4390298018

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.